1. Introduction {#sec1}
===============

Porphyrin plays an important role in the biosynthesis of many pigments crucial for plant survival, during which process protoporphyrinogen oxidase (PPO) is an essential catalytic enzyme for the conversion from porphyrin to chlorophyll or heme.^[@ref1]−[@ref3]^ In recent years, PPO-inhibiting herbicides have fueled tremendous interest in the field of agrochemical discovery as novel target-based pesticides.^[@ref4]^ The chemical structure of these herbicides including diphenylethers, phenylphthalimides, phenylpyrazole, oxazolidinediones, and so on can be generally summarized as follows:^[@ref5]^ (i) a heterocycle or heterocyclic ketone with one or more nitrogen atoms; (ii) a polysubstituted benzene ring linking with the nitrogen atom of the previous heterocycle, such as azafenidin, butafenacil, and profluazol ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).

![Chemical structures of azafenidin, butafenacil, profluazol, **A--F**, and temozolimide.](ao9b02495_0001){#fig1}

In our previous work, pyrazolotetrazinone (**A**), isoxazoltetrazinone (**B**), and pyrazolotriazinone (**C**) derivatives, which further demonstrated they acted on PPO enzyme, were designed and synthesized according to the bioisosteric principle, and some of these compounds provided good control of weeds.^[@ref6],[@ref7]^ Nonetheless, their translation to the application has severely hampered because of the poor selectivity between crops and grasses. Herein, we report the design and synthesis of novel 1*H*-purin-6(9*H*)-one (**D**) and 3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**E**) derivatives, followed by herbicidal activity assay against *Amaranthus retroflexus*, *Bactris campestris*, *Digitaria sanguinalis,* and *Echinochloa crusgalli*. However, most of the novel compounds exhibited moderate activity in primary herbicidal bioassay, but this depressing result stimulated us to explore their bioactivity in other aspects further. Temozolomide ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), one of azolotetrazinones antitumor agents highly effective on many kinds of cancer cell lines including brain tumors, leukemia, melanoma, lymphoma, and solid tumors,^[@ref8]−[@ref10]^ inspired our interest because of its high similarity to the general chemical structure of PPO-inhibiting herbicides listed above. Consequently, initial exploration to their antitumor activity was carried out and the structure--activity relationships (SAR) were also discussed using statistical methods based on the analysis of relatively superior bioactivity results.

2. Results and Discussion {#sec2}
=========================

2.1. Synthesis {#sec2.1}
--------------

The synthetic route of **7a--o** and **8a--m** was shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. Intermediate **2** was obtained by reduction with sodium thiosulfate in an alkaline solution condition with a pH of 8--9 of water and saturated sodium bicarbonate. During the process, it was found that temperature had a great influence on the yield and properties of products. As the reaction temperature decreased from 35 to 15 °C, the yield increased and the color of the product became lighter. A possible mechanism from **2** to **3** was reasonably speculated ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The construction of imidazole ring A had mainly gone through two steps. First, imine intermediate **3a** was synthesized by the nucleophilic substitution of triethyl orthoate with amine **2** in acetonitrile under refluxing. Second, the nucleophilic addition reaction at room temperature of amine R^1^NH~2~ with the relatively positively charged carbon on the cyano group afforded the second imine intermediate **3c**, and then the nitrogen atom in R^1^NH~2~ attacked the imine first described above to form a five-membered ring **3d**, which ultimately transformed to imidazole **3** after rearrangement and proton transfer. There existed great differences between different R^1^ substituents in the aspect of work-up methods and reaction time.

![Proposed mechanism from compound **2** to **3**.](ao9b02495_0002){#fig2}

![Synthetic Route of Title Compounds\
Reagents and conditions: (a) Na~2~S~2~O~4~, NaHCO~3~, H~2~O; (b) (i) RC(OEt)~3~, MeCN, 80 °C; (ii) R^1^NH~2~, MeCN, RT; (c) NaOH, EtOH, reflux; (d) SOCl~2~, −5 to 0 °C; (e) pyridine, DCM; (f) R^2^C(OEt)~3~, Ac~2~O, reflux; (g) (i) 50% H~2~SO~4~, MeOH, RT; (ii) NaNO~2~, −5 to 0 °C.](ao9b02495_0004){#sch1}

Compound **3** was hydrolyzed and then converted to its acid chloride **5**, which reacted directly with substituted aniline **15** in dichloromethane in the presence of pyridine to furnish amide **6**. The intermediates **10--14** were synthesized as the literature described.^[@ref11]−[@ref15]^ Compound **14** was reduced by stannous chloride dihydrate in ethanol under refluxing condition to give aniline **15** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Two methods to construct ring B of title compounds were built. Amide **6** was cyclized with triethyl orthoformate or triethyl orthoacetate or triethyl orthopropionate in acetic anhydride under refluxing condition to give purinone derivatives (**7a--o**, **D** series). After being activated with 50% sulphuric acid, amide **6** was reacted with sodium nitrite to give imidazotriazinone derivatives (**8a--m**, **E** series). [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} summarized the newly synthesized compounds **D** and **E**.

###### List of Title Compounds

  no.      R            R^1^                  R^2^         no.      R            R^1^                  R^2^
  -------- ------------ --------------------- ------------ -------- ------------ --------------------- -------
  **7a**   H            PhCH~2~               CH~3~CH~2~   **7o**   CH~3~CH~2~   PhCH~2~               CH~3~
  **7b**   H            PhCH~2~               H            **8a**   H            PhCH~2~                
  **7c**   H            PhCH~2~               CH~3~        **8b**   CH~3~        *p*-FPhCH~2~           
  **7d**   CH~3~        PhCH~2~               CH~3~CH~2~   **8c**   CH~3~        *o*-FPhCH~2~           
  **7e**   CH~3~        PhCH~2~               CH~3~        **8d**   CH~3~        pyridyl                
  **7f**   CH~3~        Pyridyl               CH~3~        **8e**   CH~3~        PhCH~3~CH              
  **7g**   CH~3~        PhCH~2~               H            **8f**   CH~3~        Ph                     
  **7h**   CH~3~        2,4-difluoroPhCH~2~   CH~3~        **8g**   CH~3~        *m*-FPhCH~2~           
  **7i**   CH~3~        2,4-difluoroPhCH~2~   CH~3~CH~2~   **8h**   CH~3~        PhCH~2~CH~2~           
  **7j**   CH~3~        pyridyl               CH~3~CH~2~   **8i**   CH~3~        *p*-ClPh               
  **7k**   CH~3~        2,4-sifluoroPhCH~2~   H            **8j**   CH~3~        2,4-difluoroPhCH~2~    
  **7l**   CH~3~        Pyridyl               H            **8k**   CH~3~        PhCH~2~                
  **7m**   CH~3~CH~2~   PhCH~2~               CH~3~CH~2~   **8l**   CH~3~        *p*-ClPhCH~2~          
  **7n**   CH~3~CH~2~   PhCH~2~               H            **8m**   CH~3~CH~2~   PhCH~2~                

2.2. Herbicidal Activity {#sec2.2}
------------------------

Percent inhibition of title compounds against *A. retroflexus*, *B. campestris*, *D. sanguinalis*, and *E. crusgalli* at a concentration of 1500 g/ha was shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. Compounds **7d**, **7e**, and **7f** exhibited relatively better herbicidal activity, and among them, compound **7d** showed 70.4% inhibition activity against *A. retroflexus* in postemergence treatments. Nevertheless, no title compound was found to display 100% inhibition rate at such relatively high screening concentration. In a word, the evaluation results of herbicidal activity were less satisfied; hence, further herbicidal activity tests were not carried out ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

![Synthesis Route of Common Intermediate **15**\
Reagents and conditions: (a) NCS, AlCl~3~,DCM; (b) propyl chlorocarbonate, Et~3~N, DCM, −5 to 0 C; (c) 98% H~2~SO~4~, 65% HNO~3~, −5 to 0 C; (d) NaOH, EtOH, RT; (e) K~2~CO~3~, 80% propargyl bromide in toluene, DMF; (f) SnCl~2~, EtOH, reflux.](ao9b02495_0005){#sch2}

###### Herbicidal Activity of Title Compounds (Percent Inhibition) (Rate = 1500 g/ha)[a](#t2fn1){ref-type="table-fn"}

                *A. retroflexus*   *B. campestris*   *D. sanguinalis*   *E. crusgalli*                        
  ------------- ------------------ ----------------- ------------------ ---------------- ------ ------ ------ ------
  **7a**        2                  20                0                  0                0      0      3.4    5.4
  **7b**        0                  15                0                  4.9              6.2    12.1   8.1    0
  **7c**        0                  5                 0                  5.6              8.4    11.6   11.1   4.2
  **7d**        22.8               70.4              20.1               10.2             2.2    34.5   27     21.5
  **7e**        31                 66.4              18.1               16.6             0      12.6   10.9   26.3
  **7f**        11.6               61.5              18.6               16.4             0      15.5   0      21.2
  **7g**        31                 48.1              16.6               24.5             0      21.5   22.3   13.5
  **7h**        14.7               20                9                  0                0      0      16.7   0
  **7i**        1.6                20                13.8               21.1             0      0      13.4   0
  **7j**        18.9               15.6              20.8               0                0      9.6    18.7   1.1
  **7k**        30                 15                5.6                0                30.8   0      14     4.7
  **7l**        9.5                0                 23.7               8.3              0      0      13.8   16.3
  **7m**        10.3               34.5              20.5               27.8             0      9.9    20.4   34.7
  **7n**        40.7               19.7              14.4               22.1             17.6   1.7    15.6   40.9
  **7o**        0                  18.5              7.5                32.5             3.5    0      12.8   33.2
  **8a**        0                  25.9              7.1                0                21.4   8.5    20.4   13.4
  **8b**        20.8               37.4              1.2                0                15.9   14.3   11.6   4.7
  **8c**        0                  35.9              0                  8.8              0      0      0      0
  **8d**        10.5               33.9              14.9               0                17.1   14.1   14.8   14.9
  **8e**        6.2                32.8              0                  0                19     12.6   6.2    3.3
  **8f**        0                  28.1              0                  0                0      0      9.6    0
  **8g**        0                  23.7              0                  0                12.2   31.6   3.7    10.2
  **8h**        2.1                20.2              5.7                12.4             25.3   7.8    8.1    31.5
  **8i**        0                  9.4               0                  0                0      13.8   2.3    25.8
  **8j**        10                 5                 0                  0                0      1.4    16     0
  **8k**        0                  0                 0                  0                0      0      0      0
  **8l**        24.5               0                 0                  0                0      0      0      0
  **8m**        14.5               29.9              21.6               18.4             0      6.5    8.1    28.7
  flumioxazin   100                100               100                100              100    100    100    100

Pre, preemergence; post, postemergence.

2.3. Antitumor Activity {#sec2.3}
-----------------------

The cell lines used in vitro antitumor activities were liver hepatocellular carcinoma HepG-2 and U-118 MG strocytic glioblastoma, and the results were listed in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}. In order to evaluate the tumor control efficacy, the inhibition rates of title compounds at the concentration of 20 μM were categorized and sorted into three levels: A (with percentage 70--100), B (with percentage 40--70), and C (with percentage 0--40). After calculating statistically, it turned out that percentages of antitumor activity against HepG-2 sorted into level A, B were 59.3 and 25.9%, respectively. Similarly, percentages against U-118 MG were 39.1 and 21.7%. This indicated that most of title compounds showed potent inhibitory activity against HepG-2 and U-118 MG at 20 μM. Among them, compounds **7d**, **7h**, **7i**, and **7k** displayed comparable activity against HepG-2 to positive control temozolomide with inhibition ratios of 99.0, 99.0, 99.9, and 98.1%, respectively. It was worth mentioning that some compounds showed better inhibitory effect on U-118 MG than temozolomide. For instance, the inhibition rates of **7i**, **8i**, and **8l** were 98.2%, 92.9, and 100%, respectively. IC~50~ values of compounds with inhibition ratios classified into level A were further investigated. Compounds **7d**, **7g**, **7h**, **7i**, **7k**, **7m**, and **7n** against HepG-2 and all of the chosen compounds against U-118 MG (**7a**, **7c**, **7i**, **7m**, **8e**, **8g**, **8i**, and **8l**) exhibited prominent anticancer activity with their IC~50~ values lower than that of temozolomide. Seven compounds (**7a**, **7c**, **7i**, **7m**, **8e**, **8g**, and **8l**) exhibited a good inhibitory effect on both HepG-2 and U-118 MG cell lines. Especially, **7i** displayed excellent antitumor activities inhibiting HepG-2 and U-118 MG with IC~50~ values of 2.0 and 3.8 μM, respectively.

###### Antitumor Activity of Title Compounds against HepG-2 and U-118 MG Cell Lines

                                            20[a](#t3fn1){ref-type="table-fn"}   IC~50~ (μM)   log IC~50~ (μM)                                                                       
  ----------------------------------------- ------------------------------------ ------------- ---------------------------------- ------------------------------------ ------- ----- ------
  **7a**                                    79.2                                 79.7          7.3                                19.0                                 0.9     1.3   2.6
  **7b**                                    50.1                                 16.6          [c](#t3fn3){ref-type="table-fn"}                                                       
  **7c**                                    75.7                                 76.7          4.2                                33.8                                 1.0     1.5   8.1
  **7d**                                    99.0                                 68.6          0.5                                                                     --0.3          
  **7e**                                    85.9                                 N             5.0                                                                     2.0            
  **7f**                                    20.6                                 N                                                                                                    
  **7g**                                    77.2                                 37.1          2.7                                                                     0.4            
  **7h**                                    99.0                                 25.6          1.9                                                                     0.3            
  **7i**                                    99.9                                 98.2          2.0                                3.8                                  0.3     0.6   1.9
  **7j**                                    65.0                                 2.3                                                                                                  
  **7k**                                    98.1                                 46.5          0.4                                                                     --0.4          
  **7l**                                    N[b](#t3fn2){ref-type="table-fn"}    19.7                                                                                                 
  **7m**                                    86.2                                 84.4          3.1                                12.0                                 0.5     1.1   3.9
  **7n**                                    74.2                                 60.8          3.5                                                                     1.9            
  **7o**                                    79.7                                 47.4          15.1                                                                    1.2            
  **8a**                                    48.5                                 21.7                                                                                                 
  **8b**                                    81.4                                 88.4          15.0                               ND[d](#t3fn4){ref-type="table-fn"}   1.2            
  **8c**                                    50.0                                 29.6                                                                                                 
  **8d**                                    63.1                                 N                                                                                                    
  **8e**                                    76.5                                 89.4          4.2                                13.2                                 0.6     1.1   3.2
  **8f**                                    50.2                                 N                                                                                                    
  **8g**                                    76.0                                 76.5          31.7                               20.2                                 0.4     1.3   0.6
  **8h**                                    22.1                                 15.6                                                                                                 
  **8i**                                    65.7                                 92.9                                             2.4                                          0.4    
  **8j**                                    10.2                                 N                                                                                                    
  **8k**                                    14.6                                 27                                                                                                   
  **8l**                                    83.4                                 100           10.5                               6.0                                  1.0     0.8   0.6
  **8m**                                    71.6                                 49.4          31.5                                                                    1.5            
  Control[f](#t3fn6){ref-type="table-fn"}   100                                  62.5          3.9                                52.1                                 0.6     1.7   13.4

Inhibition rate (%) at 20 μM.

Compound showing an inhibition rate \<0.

Not tested.

Not determined.

SI = IC~50~ (U-118 MG)/IC~50~ (HepG-2).

Temozolomide.

2.4. Structure--Activity Relationships {#sec2.4}
--------------------------------------

### 2.4.1. Antitumor Activity against HepG-2 {#sec2.4.1}

Percentage (%) of compounds sorted into levels A, B, and C were counted and showed in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}. When R^1^ was fixed as the benzyl group, the introduction of fluorine atom in the benzene ring could improve the activity and the sequence was para \> meta \> ortho, concretely, shown as **8b** \> **8c** \> **8g**. The similar trend for the chlorine atom in the benzene ring could also be seen from **8i** \> **8f** and **8l** \> **8k**. For the bridging bond between benzene ring and nitrogen atom on ring A, the corresponding sequence was PhCH~3~CH (**8e**) \> Ph (**8f**) \> PhCH~2~CH~2~ (**8h**) \> PhCH~2~ (**8k**), which indicated that a bulky bridging bond was favorable to the improvement of activity. However, there was no definite rule about the influence of bridging length on the activity, probably because of the enhancement of activity from the electronic conjugation effect between benzene and imidazole ring A. The broad bioactivity of nitrogen-containing heterocycles in drugs and fine chemicals led to the introduction of the pyridyl group into R^1^. Keeping the other chemical structure consistent with each other, compounds with pyridyl in R^1^ possessed higher activity regarding **D** series purinone derivatives and **E** series imidazotriazinone derivatives had the opposite trend, which was concluded from biological activity of some related compounds (**7e**, **7f**, **7d**, **7j**, **8d**, and **8k**). As shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}, when R was fixed as CH~2~CH~3~, all of compounds were classified into level A, similarly, 52.6% as CH~3~, 50% as H, from a statistical point of view, which indicated that the lengthening of the R carbon chain contributes significantly to the increase of activity. **D** series (80%) were sorted into level A when R^2^ was fixed as CH~3~ and CH~2~CH~3~, 75% as H. In addition, 20% sorted into level B as CH~2~CH~3~. Therefore, **D** series purinone derivatives with a longer R^2^ group on ring B could exhibit better inhibition activity, for example, **7f** with CH~3~ was about 3-fold less potent than **7j** with CH~2~CH~3~.

![Percentage (%) of compounds sorted into level A, B, C.](ao9b02495_0003){#fig3}

### 2.4.2. Antitumor Activity against U-118 MG {#sec2.4.2}

As shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}, after statistical analysis, the bioactivity of title compounds indicated that shorter R and longer R^2^ both had higher probability possessing high activity. For instance, compound **7a** (R = H, R^2^ = CH~2~CH~3~) displayed an inhibition rate of 79.9% at 20 μM and IC~50~ value of 19.0 μM, which was a relatively high activity. For R^1^, it has the same trend regarding the effect of halogen atom on antitumor activity as discussed above. As shown in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, compounds **8i**, **8l** with chlorine atom and **7i** with 2,4-difluorobenzyl showed higher activity than their analogues with IC~50~ values of 2.4, 6.0, and 3.8 μM, respectively, which were much lower than that of temozolomide (IC~50~ = 52.1 μM). Surprisingly, compounds **7e**, **7g**, and **7h**, which had favorable activity against HepG-2 (85.9, 77.2, and 99.9% at 20 μM, respectively) showed low activity against U-118 MG with inhibition rate \<40%. For **D** series purinone derivatives, percent inhibition against HepG-2 sorted into level A accounted for 78.6%, and for 30.7% against U-118 MG. The corresponding data of **E** series imidazotriazinone derivatives were 58.5 and 50%. In other words, **D** series showed better activity than **E** series regarding cancer control, which was consistent to the hypothesis of higher anticancer activity induced by better biocompatibility of purinone derivatives. Most of compounds were more sensitive to HepG-2 cells than U-118 MG cells in vitro, which was summarized by the analysis mentioned above. Compound **7c** showed highest selectivity to HepG-2 with a selectivity index (SI) of 8.05 ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}).

3. Conclusions {#sec3}
==============

In summary, 15 novel 1*H*-purin-6(9*H*)-ones (**D**) and 13 3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-ones (**E**) were designed and synthesized. Compound **7d** showed highest herbicidal activity against *A. retroflexus* in postemergence treatments. Most of the compounds showed good antitumor activity against HepG-2 and U-118 MG cells. One of the most promising compounds shows lower IC~50~ values than that of temozolomide. **7i** exhibited excellent activity inhibiting both HepG-2 and U-118 MG cell lines. The SAR study indicated that introduction of halogen atoms, a bulky bridging bond between benzene ring and nitrogen atom on ring A, longer R^2^ substituents were all favorable to the improvement of antitumor activity. Given our study and the good biocompatibility of purinone derivatives, **7i** can serve as a lead compound to search highly active antitumor agents in our group.

4. Experimental Section {#sec4}
=======================

4.1. Synthetic Experiments {#sec4.1}
--------------------------

### 4.1.1. General Methods {#sec4.1.1}

^1^H NMR and ^13^C NMR spectra were recorded at 400 MHz using a Bruker AV 400 spectrometer (Bruker CO., Switzerland) in CDCl~3~ or DMSO-*d*~6~ solution with tetramethylsilane as the internal standard, and chemical shift values (δ) were given in ppm. High-resolution mass spectrometry (HRMS) data were obtained on a Varian QFT-ESI instrument. The melting points were determined on an X-4 binocular microscope melting point apparatus (Beijing Tech Instruments Co., Beijing, China) and were uncorrected. Reagents were all analytically or chemically pure. All solvents and liquid reagents were dried by standard methods in advance and distilled before use.

### 4.1.2. Ethyl 2-Amino-2-cyanoacetate (**2**) {#sec4.1.2}

Sodium thiosulfate (62.5 g, 0.352 mol) was added in batches to a solution of ethyl cyano-(hydroxyimino)acetate (50 g, 0.352 mol) in saturated NaHCO~3~ (640 mL) and H~2~O (150 mL) and stirred at room temperature for 1 h. More sodium thiosulfate (62.5 g) was added every 2 h until the reaction was completely monitored by thin-layer chromatography (TLC). The solution was extracted with DCM and the organic extracts were dried over Na~2~SO~4~ and concentrated to give **2** (28.42 g, 63.1%) as light yellow oil. ^1^H NMR (400 MHz, CDCl~3~): δ 4.46 (s, 1H, CHNH~2~), 4.34 (q, *J* = 7.1 Hz, 2H, OC*H*~2~CH~3~), 2.03 (s, 2H, CHNH~2~), 1.36 (t, *J* = 7.2 Hz, 3H, OCH~2~C*H*~3~).

### 4.1.3. Ethyl 5-Amino-1-benzyl-2-methyl-1*H*-imidazole-4-carboxylate (**3--1**) {#sec4.1.3}

A solution of triethyl orthoacetate (13.45 g, 81.25 mmol) and ethyl 2-amino-2-cyanoacetate (9.46 g, 78.87 mmol) in 120 mL of acetonitrile was heated under reflux for 1 h. After cooled down to room temperature, benzyl amine (8.89 g, 0.19 mmol) was added. Stirred at room temperature for overnight, solid was precipitated out. Filtration and recrystallization with anhydrous ethanol gave **3--1** as a white solid (8.52 g, 44.5%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.42--7.31 (m, 3H, Ar-H), 7.08 (d, *J* = 6.8 Hz, 2H, Ar-H), 4.99 (s, 2H, NCH~2~), 4.72 (br s, 1H, NH~2~), 4.36 (q, *J* = 7.1 Hz, 2H, C*H*~2~CH~3~), 2.35 (s, 3H, CH~3~), 1.40 (t, *J* = 7.1 Hz, 3H, CH~2~C*H*~3~).

### 4.1.4. Ethyl 5-Amino-1-benzyl-2-ethyl-1*H*-imidazole-4-carboxylate (**3--2**) {#sec4.1.4}

^1^H NMR (400 MHz, CDCl~3~): δ 7.42--7.31 (m, 3H, Ar-H), 7.09 (d, *J* = 6.8 Hz, 2H, Ar-H), 5.01 (s, 2H, NCH~2~), 4.71 (s, 2H, NH~2~), 4.37 (q, *J* = 7.1 Hz, 2H, OC*H*~2~CH~3~), 2.68 (q, *J* = 7.5 Hz, 2H, imidazole-C*H*~2~CH~3~), 1.41 (t, *J* = 7.1 Hz, 3H, OCH~2~C*H*~3~), 1.28 (t, *J* = 7.5 Hz, 3H, imidazole-CH~2~C*H*~3~).

### 4.1.5. Ethyl 5-Amino-2-methyl-1-phenyl-1*H*-imidazole-4-carboxylate (**3--3**) {#sec4.1.5}

A solution of triethyl orthoacetate (26.23 g, 162.23 mmol) and ethyl 2-amino-2-cyanoacetate (18.45 g, 144.07 mmol) in 90 mL of acetonitrile was heated at reflux for 1 h. After cooled down to room temperature, aniline (15.10 g, 158.48 mmol) was added. The mixture was stirred for 18 h at room temperature. The resulting solution was evaporated under reduced pressure, dissolved with DCM, washed with 10% sodium hydroxide solution followed by brine. The organic layer was separated, dried over Na~2~SO~4~, and then the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give **3--3** (5.85 g, 13.5%) as a white solid. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.57 (m, 3H, Ar-H), 7.40 (d, *J* = 7.7 Hz, 2H, Ar-H), 5.66 (s, 2H, NH~2~), 4.18 (q, *J* = 7.0 Hz, 2H, C*H*~2~CH~3~), 1.98 (s, 3H, CH~3~), 1.25 (t, *J* = 7.0 Hz, 3H, CH~2~C*H*~3~).

### 4.1.6. Ethyl 5-Amino-2-methyl-1-(1-phenylethyl)-1*H*-imidazole-4-carboxylate (**3--4**) {#sec4.1.6}

A solution of triethyl orthoacetate (33.66 g, 203.58 mmol) and ethyl 2-amino-2-cyanoacetate (23.70 g, 185.07 mmol) in 90 mL of acetonitrile was heated under reflux for 1 h. After cooled down to room temperature, 1-phenyl ethylamine (25.0 g, 203.58 mmol) was added. The mixture was stirred for 24 h at room temperature. The resulting solution was evaporated under reduced pressure, dissolved with DCM, washed with 10% sodium hydroxide solution followed by brine. The organic layer was separated, dried over Na~2~SO~4~, and then the solvent was evaporated under reduced pressure. The residue was recrystallized with anhydrous ethanol to give **3--4** as a white solid (6.65 g, 14.5%).^1^H NMR (400 MHz, CDCl~3~): δ 7.42--7.30 (m, 3H, Ar-H), 7.22 (d, *J* = 7.8 Hz, 2H, Ar-H), 5.42 (q, *J* = 7.1 Hz, 1H, C*H*CH~3~), 4.48 (br s, 2H, NH~2~), 4.30 (q, *J* = 7.1 Hz, 2H, C*H*~2~CH~3~), 2.38 (s, 3H, CH~3~), 1.86 (d, *J* = 7.2 Hz, 3H, CHC*H*~3~), 1.35 (t, *J* = 7.1 Hz, 3H, CH~2~C*H*~3~).

### 4.1.7. 5-Amino-1-benzyl-2-methyl-1*H*-imidazole-4-carboxylic Acid (**4--1**) {#sec4.1.7}

A solution of ethyl 5-amino-1-benzyl-2-methyl-1*H*-imidazole-4-carboxylate (4.54 g, 17.52 mmol) in ethanol (180 mL) and 0.5 M NaOH solution (180 mL) was refluxed for 10 h. Volatiles were evaporated, water (5 mL) was added, and 5% HCl solution was added until pH = 5. The off-white solid precipitated was filtered and washed with ice water. This material was dried under vacuum at ambient temperature to give **4--1** (2.63 g, 65.0%) as a yellow solid. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.98 (s, 2H, COOH), 7.32 (m, 3H, Ar-H), 7.08 (d, *J* = 7.4 Hz, 2H, Ar-H), 6.02 (s, 2H, NH~2~), 5.09 (s, 2H, NCH~2~), 2.07 (s, 3H, CH~3~).

### 4.1.8. 5-Amino-1-benzyl-2-methyl-1*H*-imidazole-4-carbonyl Chloride (**5--1**) {#sec4.1.8}

5-Amino-1-benzyl-2-methyl-1*H*-imidazole-4-carboxylic acid (2.63 g, 11.38 mmol) was dissolved in 10 mL of thionyl chloride at 0 °C and stirred for 3 h. The resulting solution was evaporated to afford the crude product **5--1** (2.01 g, 70.5%) as a yellow solid, which was directly used for the next step without further purification.

### 4.1.9. 5-Amino-1-benzyl-*N*-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-2-methyl-1*H*-imidazole-4-carboxamide (**6--1**) {#sec4.1.9}

5-Amino-1-benzyl-2-methyl-1*H*-imidazole-4-carbonyl chloride (2.01 g, 8.02 mmol) was added to a solution of 4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)aniline (2.50 g, 11.38 mmol) and pyridine (3 mL) in dichloromethane (35 mL) at 0 °C. The solution was stirred overnight until TLC showed the reaction to be complete. The resulting mixture was washed with 1 M HCl, saturated NaHCO~3~, brine, and dried over Na~2~SO~4~. The solvent was evaporated under reduced pressure and the resulting crude residue was purified by flash column chromatography on silica gel to give **3--3** (2.31 g, 70%) as a white solid. ^1^H NMR (400 MHz, CDCl~3~): δ 8.82 (s, 1H, CONH), 8.36 (d, *J* = 6.9 Hz, 1H, Ar-H), 7.36 (m, 3H, Ar-H), 7.16 (d, *J* = 10.2 Hz, 1H, Ar-H), 7.09 (d, *J* = 7.0 Hz, 2H, Ar-H), 4.99 (s, 2H, NCH~2~), 4.78 (d, *J* = 2.3 Hz, 2H, C*H*~2~C≡CH), 4.75 (s, 2H, NH~2~), 4.12 (t, *J* = 7.1 Hz, 1H, CH~2~C≡C*H*), 2.35 (s, 3H, CH~3~).

### 4.1.10. 4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)aniline (**15**) {#sec4.1.10}

Stannous chloride dihydrate (131.82 g, 0.574 mol) was added to the solution of 1-chloro-5-fluoro-4-nitro-2-(prop-2-yn-1-yloxy)benzene (26.29 g, 0.114 mol) in ethanol (230 mL). The mixture was heated to 70 °C and refluxed until the reaction was completely monitored by TLC. The reaction mixture was poured into a large quantity of iced water and neutralized with 10% NaOH solution to pH = 7--8. The precipitated white solid was filtered and washed with EtOAc (3 × 30 mL). The organic layer was dried over Na~2~SO~4~ and concentrated under reduced pressure to afford **15** (22.28 g, 98.2%) as a brown solid. ^1^H NMR (400 MHz, CDCl~3~): δ 7.04 (d, *J* = 10.3 Hz, 1H, Ar-H), 6.56 (d, *J* = 8.0 Hz, 1H, Ar-H), 4.70 (d, 2H, C*H*~2~C≡CH), 3.63 (s, 2H, NH~2~), 2.56 (t, *J* = 2.4 Hz, 1H, CH~2~C≡C*H*).

### 4.1.11. 1*H*-Purin-6(9*H*)-one (**D**) {#sec4.1.11}

Amide **6** (1.17 mmol) was dissolved in acetic anhydride (6 mL) and triethyl orthoate (6 mL). The reaction solution was heated to 140 °C and refluxed until the reaction was completely monitored by TCL. The resulting solution was concentrated under reduced pressure and resulting crude residue was purified by flash column chromatography on silica gel to give **D** as a light yellow solid.

### 4.1.12. 9-Benzyl-1-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-2-ethyl-1*H*-purin-6(9*H*)-one (**7a**) {#sec4.1.12}

It was obtained in 78.2% yield; mp 164--165 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.30 (s, 1H, purine-H), 7.80 (d, *J* = 9.1 Hz, 1H, Ar-H), 7.54 (d, *J* = 6.7 Hz, 1H, Ar-H), 7.44 (d, *J* = 7.4 Hz, 2H, Ar-H), 7.39 (t, *J* = 7.3 Hz, 2H, Ar-H), 7.32 (t, *J* = 7.0 Hz, 1H, Ar-H), 5.41 (s, 2H, NCH~2~), 4.91 (d, *J* = 2.0 Hz, 2H, C*H*~2~C≡CH), 3.65 (t, *J* = 1.4 Hz, 1H, CH~2~C≡C*H*), 2.64--2.54 (m, 1H, purine-C*H*~2~CH~3~), 2.39--2.29 (m, 1H, purine-C*H*~2~CH~3~), 1.16 (t, *J* = 7.1 Hz, 3H, purine-CH~2~C*H*~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): 159.45, 156.57, 151.85 (d, ^1^*J*~C--F~ = 245.9 Hz), 150.04 (d, ^3^*J*~C--F~ = 2.1 Hz), 147.69, 141.24, 137.12, 129.22, 128.50, 128.47, 124.20 (d, ^2^*J*~C--F~ = 15.0 Hz), 123.65 (d, ^3^*J*~C--F~ = 9.8 Hz), 121.57, 118.58 (d, ^2^*J*~C--F~ = 24.7 Hz), 116.68, 79.66, 78.67, 57.58, 47.14, 28.80, 10.86; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~23~H~18~ClFN~4~O~2~, 459.0995; found, 459.0998.

### 4.1.13. 9-Benzyl-1-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-1*H*-purin-6(9*H*)-one (**7b**) {#sec4.1.13}

It was obtained in 72.5% yield; mp 122--126 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.39 (s, 1H, purine-H), 8.37 (s, 1H, imidazole-H), 7.79 (d, *J* = 9.2 Hz, 1H, Ar-H), 7.59 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.39--7.31 (m, 5H, Ar-H), 5.45 (s, 2H, NCH~2~), 4.92 (d, *J* = 1.8 Hz, 2H, C*H*~2~C≡CH), 3.65 (t, *J* = 1.4 Hz, 1H, CH~2~C≡C*H*); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.95, 151.40 (d, ^1^*J*~C--F~ = 247.8 Hz), 149.36 (d, ^3^*J*~C--F~ = 2.5 Hz), 148.14, 147.48, 141.40, 136.55, 128.76, 127.93, 127.56, 124.04 (d, ^2^*J*~C--F~ = 15.2 Hz), 123.00 (d, ^3^*J*~C--F~ = 6.0 Hz), 117.85 (d, ^2^*J*~C--F~ = 24.0 Hz), 115.66, 79.23, 78.10, 59.73, 57.26, 54.88, 46.75, 20.73, 14.05; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~21~H~14~ClFN~4~O~2~, 431.0682; found, 431.0685.

### 4.1.14. 9-Benzyl-1-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-2-methyl-1*H*-purin-6(9*H*)-one (**7c**) {#sec4.1.14}

It was obtained in 79.1% yield; mp 125--126 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.26 (s, 1H, purine-H), 7.80 (d, *J* = 8.6 Hz, 1H, Ar-H), 7.55 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.43--7.31 (m, 5H, Ar-H), 5.41 (s, 2H, NCH~2~), 4.92 (d, *J* = 2.0 Hz, 2H, C*H*~2~C≡CH), 3.65 (t, *J* = 2.2 Hz, 1H, CH~2~C≡C*H*), 2.26 (s, 3H, purine-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 156.54, 156.14, 151.71 (d, ^1^*J*~C--F~ = 246.1 Hz), 150.01 (d, ^3^*J*~C--F~ = 2.4 Hz), 147.70, 141.33, 137.19, 129.27, 128.39, 127.99, 124.69 (d, ^2^*J*~C--F~ = 15.0 Hz), 123.66 (d, ^3^*J*~C--F~ = 9.9 Hz), 121.69, 118.62 (d, ^2^*J*~C--F~ = 24.8 Hz), 116.54, 79.69, 78.67, 57.59, 46.89, 24.16; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~22~H~16~ClFN~4~O~2~, 423.1019; found, 423.1023.

### 4.1.15. 9-Benzyl-1-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-2-ethyl-8-methyl-1*H*-purin-6(9*H*)-one (**7d**) {#sec4.1.15}

It was obtained in 78.4% yield; mp 134--135 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.81 (d, *J* = 9.1 Hz, 1H, Ar-H), 7.55 (d, *J* = 6.8 Hz, 1H, Ar-H), 7.41--7.36 (m, 2H, Ar-H), 7.34--7.30 (m, *J* = 8.1 Hz, 3H, Ar-H), 5.44 (d, *J* = 15.9 Hz, 1H, NCH~2~), 5.37 (d, *J* = 15.5 Hz, 1H, NCH~2~), 4.94 (d, *J* = 1.4 Hz, 2H, C*H*~2~C≡CH), 3.67 (t, *J* = 1.4 Hz, 1H, CH~2~C≡C*H*), 2.58 (m, 1H, purine-C*H*~2~CH~3~), 2.43 (s, 3H, imidazole-CH~3~), 2.38--2.30 (m, 1H, purine-C*H*~2~CH~3~), 1.15 (t, *J* = 7.2 Hz, 3H, purine-CH~2~C*H*~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 158.91, 156.21, 151.86 (d, ^1^*J*~C--F~ = 245.8 Hz), 150.03 (d, ^3^*J*~C--F~ = 2.0 Hz), 148.87, 148.68, 136.80, 129.34, 128.32, 127.83, 124.35 (d, ^2^*J*~C--F~ = 14.9 Hz), 123.59 (d, ^3^*J*~C--F~ = 9.8 Hz), 120.19, 118.57 (d, ^2^*J*~C--F~ = 24.7 Hz), 116.68, 79.68, 78.71, 57.59, 45.74, 28.78, 14.25, 10.94; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~24~H~20~ClFN~4~O~2~, 451.1332; found, 451.1336.

### 4.1.16. 9-Benzyl-1-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-2,8-dimethyl-1*H*-purin-6(9*H*)-one (**7e**) {#sec4.1.16}

It was obtained in 73.3% yield; mp 157--159 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.81 (d, *J* = 9.1 Hz, 1H, Ar-H), 7.56 (d, *J* = 6.7 Hz, 1H, Ar-H), 7.39 (t, *J* = 7.3 Hz, 2H, Ar-H), 7.32 (t, *J* = 7.0 Hz, 1H, Ar-H), 7.23 (d, *J* = 7.4 Hz, 2H, Ar-H), 5.44 (d, *J* = 16.2 Hz, 1H, NCH~2~), 5.37 (d, *J* = 16.2 Hz, 1H, NCH~2~), 4.95 (d, *J* = 2.0 Hz, 2H, C*H*~2~C≡CH), 3.67 (t, *J* = 2.2 Hz, 1H, CH~2~C≡C*H*), 2.40 (s, 3H, imidazole-CH~3~), 2.26 (s, 3H, purine-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 155.68, 155.04, 151.22 (d, ^1^*J*~C--F~ = 246.2 Hz), 149.53 (d, ^3^*J*~C--F~ = 2.0 Hz), 148.43, 148.18, 136.24, 128.86, 127.74, 126.87, 124.33 (d, ^2^*J*~C--F~ = 15.0 Hz), 123.10 (d, ^3^*J*~C--F~ = 9.8 Hz), 119.84, 118.11 (d, ^2^*J*~C--F~ = 24.9 Hz), 116.03, 79.20, 78.21, 57.11, 45.06, 23.60, 13.68; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~23~H~18~ClFN~4~O~2~, 459.0995; found, 459.0999.

### 4.1.17. 1-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-2,8-dimethyl-9-(pyridin-2-ylmethyl)-1*H*-purin-6(9*H*)-one (**7f**) {#sec4.1.17}

It was obtained in 77.1% yield; mp 132--133 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.51 (d, *J* = 4.9 Hz, 1H, pyridine-H), 7.85--7.79 (m, 2H, pyridine-H, Ar-H), 7.83 (d, *J* = 8.84 Hz, 1H, Ar-H), 7.82 (dd, *J* = 17.3, 8.4 Hz, 2H, pyridine-H), 7.56 (d, *J* = 6.8 Hz, 1H, Ar-H), 7.38--7.30 (m, 2H, pyridine-H), 5.53 (d, *J* = 16.8 Hz, 1H, NCH~2~), 5.48 (d, *J* = 16.7 Hz, 1H, NCH~2~), 4.95 (d, *J* = 1.4 Hz, 2H, C*H*~2~C≡CH), 3.66 (t, *J* = 1.4 Hz, 1H, CH~2~C≡C*H*), 2.42 (s, 3H, imidazole-CH~3~), 2.23 (s, 3H, purine-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 156.18, 155.59, 155.33, 151.73 (d, ^1^*J*~C--F~ = 246.1 Hz), 150.03 (d, ^3^*J*~C--F~ = 2.2 Hz), 149.95, 149.53, 148.77, 137.73, 124.83 (d, ^2^*J*~C--F~ = 15.0 Hz), 123.58 (d, ^3^*J*~C--F~ = 9.9 Hz), 123.44, 122.09, 120.29, 118.58 (d, ^2^*J*~C--F~ = 24.8 Hz), 116.54, 79.66, 78.69, 57.61, 47.10, 24.03, 14.22; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~22~H~17~ClFN~5~O~2~, 438.1128; found, 438.1130.

### 4.1.18. 9-Benzyl-1-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-8-methyl-1*H*-purin-6(9*H*)-one (**7g**) {#sec4.1.18}

It was obtained in 72.6% yield; mp 192--194 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.38 (s, 1H, purine-H), 7.80 (d, *J* = 9.2 Hz, 1H, Ar-H), 7.60 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.39 (t, *J* = 7.3 Hz, 1H, Ar-H), 7.32 (t, *J* = 7.0 Hz, 1H, Ar-H), 7.25 (d, *J* = 7.4 Hz, 2H, Ar-H), 5.43 (s, 2H, NCH~2~), 4.94 (d, *J* = 2.0 Hz, 2H, C*H*~2~C≡CH), 3.67 (t, *J* = 2.2 Hz, 1H, CH~2~C≡C*H*), 2.44 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 155.09, 151.93 (d, ^1^*J*~C--F~ = 247.8 Hz), 149.88 (d, ^3^*J*~C--F~ = 2.4 Hz), 149.58, 148.96, 148.08, 136.67, 129.37, 128.30, 127.49, 124.70 (d, ^2^*J*~C--F~ = 14.7 Hz), 123.49 (d, ^3^*J*~C--F~ = 9.8 Hz), 122.20, 118.35 (d, ^2^*J*~C--F~ = 24.7 Hz), 116.17, 79.74, 78.65, 57.82, 45.92, 14.25; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~22~H~16~ClFN~4~O~2~, 423.1019; found, 423.1025.

### 4.1.19. 1-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-9-(2,4-difluorobenzyl)-2,8-dimethyl-1*H*-purin-6(9*H*)-one (**7h**) {#sec4.1.19}

It was obtained in 74.4% yield; mp 132--133 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.81 (d, *J* = 9.1 Hz, 1H, Ar-H), 7.54 (d, *J* = 6.8 Hz, 1H, Ar-H), 7.37--7.31 (m, 1H, Ar-H), 7.25--7.19 (m, 8.4 Hz, 1H, Ar-H), 7.12--7.08 (m, 1H, Ar-H), 5.41 (s, 2H, NCH~2~), 4.94 (d, *J* = 1.4 Hz, 2H, C*H*~2~C≡CH), 3.67 (t, *J* = 1.4 Hz, 1H, CH~2~C≡C*H*), 2.42 (s, 3H, imidazole-CH~3~), 2.24 (s, 3H, purine-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 162.42 (dd, ^1^*J*~C--F~ = 251.1 Hz, ^3^*J*~C--F~ = 14.5 Hz), 160.36 (dd, ^1^*J*~C--F~ = 256.5 Hz, ^3^*J*~C--F~ = 14.1 Hz), 156.12, 155.51, 151.69 (d, ^1^*J*~C--F~ = 246.1 Hz), 150.03 (d, ^3^*J*~C--F~ = 2.6 Hz), 148.88, 148.69, 131.30, 131.20 (t, ^3^*J*~C--F~ = 5.1 Hz), 124.76 (d, ^2^*J*~C--F~ = 15.0 Hz), 123.63 (d, ^3^*J*~C--F~ = 9.9 Hz), 120.39, 119.96 (dd, ^2^*J*~C--F~ = 14.7 Hz, ^4^*J*~C--F~ = 3.5 Hz), 118.61 (d, ^2^*J*~C--F~ = 24.5 Hz), 116.51, 112.45 (dd, ^2^*J*~C--F~ = 21.4 Hz, ^4^*J*~C--F~ = 3.4 Hz), 104.77 (t, ^2^*J*~C--F~ = 26.0 Hz), 79.69, 78.70, 57.61, 40.63, 24.09, 14.02; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~23~H~16~ClF~3~N~4~O~2~, 495.0806; found, 495.0810.

### 4.1.20. 1-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-9-(2,4-difluorobenzyl)-2-ethyl-8-methyl-1*H*-purin-6(9*H*)-one (**7i**) {#sec4.1.20}

It was obtained in 69.6% yield; mp 157--158 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.80 (d, *J* = 9.1 Hz, 1H, Ar-H), 7.52 (d, *J* = 6.8 Hz, 1H, Ar-H), 7.40 (m, 1H, Ar-H), 7.32 (m, 1H, Ar-H), 7.12 (m, 1H, Ar-H), 5.41 (s, 2H, NCH~2~), 4.93 (d, *J* = 1.7 Hz, 2H, C*H*~2~C≡CH), 3.67 (t, *J* = 2.0 Hz, 1H, CH~2~C≡C*H*), 2.63--2.53 (m, 1H, purine-C*H*~2~CH~3~), 2.47 (s, 3H, imidazole-CH~3~), 2.36--2.28 (m, 1H, purine-C*H*~2~CH~3~), 1.12 (t, *J* = 7.2 Hz, 3H, purine-CH~2~C*H*~3~); ^13^C NMR (101 MHz, CDCl~3~): δ 162.72 (dd, ^1^*J*~C--F~ = 251.5 Hz, ^3^*J*~C--F~ = 12.1 Hz), 160.34 (dd, ^1^*J*~C--F~ = 252.5 Hz, ^3^*J*~C--F~ = 11.1 Hz), 158.67, 156.42, 151.91 (d, ^1^*J*~C--F~ = 248.5 Hz), 149.98 (d, ^3^*J*~C--F~ = 2.0 Hz), 148.44, 148.38, 131.34, 131.25 (t, ^3^*J*~C--F~ = 4.0 Hz), 125.31 (d, ^2^*J*~C--F~ = 10.1 Hz), 123.43 (d, ^2^*J*~C--F~ = 15.2 Hz), 120.53, 118.65 (d, ^2^*J*~C--F~ = 25.3 Hz), 118.62 (d, ^3^*J*~C--F~ = 3.0 Hz), 115.74, 111.82 (dd, ^2^*J*~C--F~ = 22.2 Hz, ^4^*J*~C--F~ = 3.0 Hz), 104.05 (t, ^2^*J*~C--F~ = 25.3 Hz), 77.64, 77.00, 57.38, 39.40, 28.69, 13.70, 10.66; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~24~H~18~ClF~3~N~4~O~2~, 487.1143; found, 487.1148.

### 4.1.21. 1-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-2-ethyl-8-methyl-9-(pyridin-2-ylmethyl)-1*H*-purin-6(9*H*)-one (**7j**) {#sec4.1.21}

It was obtained in 77.3% yield; mp 181--185 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.53 (d, *J* = 4.4 Hz, 1H, pyridine-H), 7.86--7.76 (m, 2H, Ar-H), 7.55 (d, *J* = 6.8 Hz, 1H, Ar-H), 7.40 (d, *J* = 7.8 Hz, 1H, pyridine-H), 7.37--7.30 (m, 1H, pyridine-H), 5.54 (d, *J* = 16.4 Hz, 1H, NCH~2~), 5.49 (d, *J* = 16.4 Hz, 1H, NCH~2~), 4.95 (d, *J* = 1.4 Hz, 2H, C*H*~2~C≡CH), 3.66 (t, 1H, *J* = 1.4 Hz, CH~2~C≡C*H*), 2.64--2.53 (m, 1H, purine-C*H*~2~CH~3~), 2.46 (s, 3H, imidazole-CH~3~), 2.36--2.28 (m, 1H, purine-C*H*~2~CH~3~), 1.10 (t, *J* = 7.2 Hz, 3H, purine-CH~2~C*H*~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 158.77, 156.22, 155.70, 151.87 (d, ^1^*J*~C--F~ = 245.9 Hz), 150.03 (d, ^3^*J*~C--F~ = 2.0 Hz), 149.97, 149.51, 148.76, 137.70, 124.36 (d, ^2^*J*~C--F~ = 15.0 Hz), 123.58 (d, ^3^*J*~C--F~ = 9.9 Hz), 123.47, 122.40, 120.15, 118.54 (d, ^2^*J*~C--F~ = 24.9 Hz), 116.68, 79.64, 78.69, 57.59, 47.31, 28.74, 14.27, 10.89; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~23~H~19~ClFN~5~O~2~, 452.1284; found, 452.1288.

### 4.1.22. 1-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-9-(2,4-difluorobenzyl)-8-methyl-1*H*-purin-6(9*H*)-one (**7k**) {#sec4.1.22}

It was obtained in 76.3% yield; mp 126--130 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.36 (s, 1H, purine-H), 7.79 (d, *J* = 9.2 Hz, 1H, Ar-H), 7.58 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.37--7.30 (m, 1H, Ar-H), 7.28--7.21 (m, 1H, Ar-H), 7.10 (t, *J* = 7.8 Hz, 1H, Ar-H), 5.45 (s, 2H, NCH~2~), 4.93 (d, *J* = 1.1 Hz, 2H, C*H*~2~C≡CH), 3.67 (t, *J* = 1.4 Hz, 1H, CH~2~C≡C*H*), 2.47 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 163.16 (dd, ^1^*J*~C--F~ = 247.9 Hz, ^3^*J*~C--F~ = 12.2 Hz), 161.10 (dd, ^1^*J*~C--F~ = 249.6 Hz, ^3^*J*~C--F~ = 12.4 Hz), 155.72, 152.59 (d, ^1^*J*~C--F~ = 247.6 Hz), 150.55 (d, ^3^*J*~C--F~ = 2.1 Hz), 150.29, 149.65, 148.74, 132.15, 132.05 (t, ^3^*J*~C--F~ = 5.1 Hz), 125.32 (d, ^2^*J*~C--F~ = 14.6 Hz), 124.18 (d, ^3^*J*~C--F~ = 9.6 Hz), 122.94, 120.60 (dd, ^2^*J*~C--F~ = 14.6 Hz, ^4^*J*~C--F~ = 3.5 Hz), 119.04 (d, ^2^*J*~C--F~ = 24.8 Hz), 116.80, 113.14 (dd, ^2^*J*~C--F~ = 21.6 Hz, ^4^*J*~C--F~ = 3.2 Hz), 105.48 (t, ^2^*J*~C--F~ = 25.8 Hz), 80.44, 79.33, 58.48, 41.30, 14.80; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~22~H~14~ClF~3~N~4~O~2~, 459.0830; found, 459.0835.

### 4.1.23. 1-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-8-methyl-9-(pyridin-2-ylmethyl)-1*H*-purin-6(9*H*)-one (**7l**) {#sec4.1.23}

It was obtained in 71.2% yield; mp 192--194 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.50 (d, *J* = 4.0 Hz, 1H, pyridine-H), 8.31 (s, 1H, purine-H), 7.85--7.76 (m, 2H, Ar-H), 7.59 (d, *J* = 6.5 Hz, 1H, Ar-H), 7.37 (d, *J* = 7.7 Hz, 1H, pyridine-H), 7.33 (t, *J* = 6.0 Hz, 1H, pyridine-H), 5.53 (s, 2H, NCH~2~), 4.93 (d, *J* = 1.4 Hz, 2H, C*H*~2~C≡CH), 3.66 (t, *J* = 2.0 Hz, 1H, CH~2~C≡C*H*), 2.47 (s, 3H, imidazole-CH~3~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 156.23, 155.77, 152.61 (d, ^1^*J*~C--F~ = 247.7 Hz), 150.89 (d, ^3^*J*~C--F~ = 2.0 Hz), 150.89, 150.55 (d, ^4^*J*~C--F~ = 2.5 Hz), 149.74, 148.59, 138.43, 125.40 (d, ^2^*J*~C--F~ = 14.6 Hz), 124.78, 124.18 (d, ^3^*J*~C--F~ = 9.5 Hz), 122.89, 124.85 (d, ^3^*J*~C--F~ = 7.3 Hz), 119.02 (d, ^2^*J*~C--F~ = 24.8 Hz), 116.83, 80.41, 79.33, 58.48, 48.11, 14.98; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~21~H~15~ClFN~5~O~2~, 424.0971; found, 424.0975.

### 4.1.24. 9-Benzyl-1-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-2,8-diethyl-1*H*-purin-6(9*H*)-one (**7m**) {#sec4.1.24}

It was obtained in 70.4% yield; mp 133--134 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.81 (d, *J* = 9.0 Hz, 1H, Ar-H), 7.55 (d, *J* = 6.5 Hz, 1H, Ar-H), 7.39 (t, *J* = 6.9 Hz, 2H, Ar-H), 7.34--7.27 (m, 3H, Ar-H), 5.45 (d, *J* = 16.0 Hz, 1H, NCH~2~), 5.39 (d, *J* = 16.0 Hz, 1H, NCH~2~), 4.95 (d, *J* = 1.4 Hz, 2H, C*H*~2~C≡CH), 3.67 (t, *J* = 1.4 Hz, 1H, CH~2~C≡C*H*), 2.82--2.69 (m, 8.5 Hz, 2H, imidazole-C*H*~2~CH~3~), 2.65--2.55 (m, 1H, purine-CH~2~CH~3~), 2.42--2.32 (m, 1H, purine-C*H*~2~CH~3~), 1.20 (t, *J* = 7.4 Hz, 3H, imidazole-CH~2~C*H*~3~), 1.15 (t, *J* = 6.9 Hz, 3H, purine-CH~2~CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 158.98, 156.35, 153.16, 151.88 (d, ^1^*J*~C--F~ = 245.9 Hz), 150.03 (d, ^3^*J*~C--F~ = 2.4 Hz), 148.72, 136.93, 129.32, 128.30, 127.69, 124.37 (d, ^2^*J*~C--F~ = 15.1 Hz), 123.63 (d, ^3^*J*~C--F~ = 9.8 Hz), 120.20, 118.58 (d, ^2^*J*~C--F~ = 24.7 Hz), 116.68, 79.66, 78.70, 57.59, 45.61, 28.79, 20.73, 11.47, 10.95; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~22~H~17~ClFN~5~O~2~, 487.1308; found, 487.1311.

### 4.1.25. 9-Benzyl-1-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-8-ethyl-1*H*-purin-6(9*H*)-one (**7n**) {#sec4.1.25}

It was obtained in 78.4% yield; mp 159--161 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.39 (s, 1H, purine-H), 7.81 (d, *J* = 9.2 Hz, 1H, Ar-H), 7.60 (d, *J* = 6.7 Hz, 1H, Ar-H), 7.38 (t, *J* = 7.3 Hz, 2H, Ar-H), 7.31 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.23 (d, *J* = 7.2 Hz, 2H, Ar-H), 5.44 (s, 2H, NCH~2~), 4.94 (d, *J* = 2.1 Hz, 2H, C*H*~2~C≡CH), 3.68 (t, *J* = 2.2 Hz, 1H, CH~2~C≡C*H*), 2.77 (q, *J* = 6.8 Hz, 2H, imidazole-CH~2~CH~3~), 1.21 (t, *J* = 7.4 Hz, 3H, imidazole-CH~2~CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 155.20, 153.79, 151.93 (d, ^1^*J*~C--F~ = 247.9 Hz), 149.87 (d, ^3^*J*~C--F~ = 2.6 Hz), 148.99, 148.11, 136.81, 129.34, 128.26, 127.36, 124.71 (d, ^2^*J*~C--F~ = 14.6 Hz), 123.47 (d, ^3^*J*~C--F~ = 9.7 Hz), 122.19, 118.35 (d, ^2^*J*~C--F~ = 24.8 Hz), 116.14, 79.74, 78.63, 57.79, 45.62, 20.73, 11.44; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~22~H~17~ClFN~5~O~2~, 459.0995; found, 459.0998.

### 4.1.26. 9-Benzyl-1-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-8-ethyl-2-methyl-1*H*-purin-6(9*H*)-one (**7o**) {#sec4.1.26}

It was obtained in 75.5% yield; mp 127--128 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.82 (d, *J* = 9.1 Hz, 1H, Ar-H), 7.56 (d, *J* = 6.8 Hz, 1H, Ar-H), 7.39 (t, *J* = 7.3 Hz, 2H, Ar-H), 7.32 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.21 (d, *J* = 7.3 Hz, 2H, Ar-H), 5.45 (d, *J* = 16.2 Hz, 1H, NCH~2~), 5.38 (d, *J* = 16.2 Hz, 1H, NCH~2~), 4.95 (d, *J* = 1.7 Hz, 2H, C*H*~2~C≡CH), 3.68 (t, *J* = 2.2 Hz, 1H, CH~2~C≡C*H*), 2.80--2.63 (m, 2H, imidazole-C*H*~2~CH~3~), 2.26 (s, 3H, purine-CH~3~), 1.19 (t, *J* = 7.4 Hz, 3H, imidazole-CH~2~C*H*~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 156.30, 155.58, 153.17, 151.72 (d, ^1^*J*~C--F~ = 246.2 Hz), 150.02 (d, ^3^*J*~C--F~ = 2.2 Hz), 148.72, 136.90, 129.34, 128.22, 127.26, 124.84 (d, ^2^*J*~C--F~ = 15.0 Hz), 123.58 (d, ^3^*J*~C--F~ = 10.0 Hz), 120.33, 118.63 (d, ^2^*J*~C--F~ = 24.9 Hz), 116.50, 79.73, 78.70, 57.58, 45.28, 24.12, 20.67, 11.42; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~22~H~17~ClFN~5~O~2~, 473.1151; found, 473.1156.

### 4.1.27. 3*H*-Imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**E**) {#sec4.1.27}

50% Sulphuric acid solution (20 mL) was added to the solution of amide **6** (1.94 mmol) in methanol (20 mL). The reaction solution was stirred overnight at room temperature. After being cooled down below 0 °C, saturated sodium nitrite solution (2 mL) was added dropwise and stirred for 2.5 h. After the reaction was completely monitored by TLC, ice water was added, and then extracted with EtOAc. The organic layer was washed with brine and dried over anhydrous Na~2~SO~4~. The solvent was removed under reduced pressure and purified by flash column chromatography on silica gel to give **E** as light yellow solids.

### 4.1.28. 7-Benzyl-3-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8a**) {#sec4.1.28}

It was obtained in 68.8% yield; mp 133--134 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.79 (s, 1H, imidazole-H), 7.84 (d, *J* = 9.3 Hz, 1H, Ar-H), 7.63 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.46 (d, *J* = 7.2 Hz, 2H, Ar-H), 7.41 (t, *J* = 7.3 Hz, 2H, Ar-H), 7.35 (t, *J* = 7.0 Hz, 1H, Ar-H), 5.69 (s, 2H, NCH~2~), 4.92 (d, *J* = 2.3 Hz, 2H, C*H*~2~C≡CH), 3.67 (t, *J* = 2.2 Hz, 1H, CH~2~C≡C*H*); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 153.39, 151.34 (d, ^1^*J*~C--F~ = 249.0 Hz), 149.90 (d, ^3^*J*~C--F~ = 2.9 Hz), 145.85, 144.70, 136.21, 129.38, 128.79, 128.37, 126.90, 125.87 (d, ^2^*J*~C--F~ = 13.9 Hz), 124.30 (d, ^3^*J*~C--F~ = 4.8 Hz), 118.52 (d, ^2^*J*~C--F~ = 24.3 Hz), 115.75, 79.78, 78.55, 57.74, 48.53; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~22~H~17~ClFN~5~O~2~, 432.0634; found, 432.0638.

### 4.1.29. 3-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-7-(4-fluorobenzyl)-6-methyl-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8b**) {#sec4.1.29}

It was obtained in 77.7% yield; mp 153--155 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.86 (d, *J* = 9.3 Hz, 1H, Ar-H), 7.63 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.43--7.40 (m, *J* = 8.6, 5.4 Hz, 2H, Ar-H), 7.24 (t, *J* = 8.8 Hz, 2H, Ar-H), 5.66 (s, 2H, NCH~2~), 4.96 (d, *J* = 2.2 Hz, 2H, C*H*~2~C≡CH), 3.69 (t, *J* = 2.2 Hz, 1H, C*H*~2~C≡CH), 2.61 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, CDCl~3~): δ 162.65 (d, ^1^*J*~C--F~ = 248.5 Hz), 153.53, 152.99, 151.51 (d, ^1^*J*~C--F~ = 252.5 Hz), 149.78 (d, ^3^*J*~C--F~ = 2.0 Hz), 145.22, 130.11 (d, ^4^*J*~C--F~ = 3.0 Hz), 129.46 (d, ^3^*J*~C--F~ = 8.1 Hz), 126.04, 125.64 (d, ^2^*J*~C--F~ = 9.1 Hz), 125.14 (d, ^3^*J*~C--F~ = 10.1 Hz), 118.51 (d, ^2^*J*~C--F~ = 23.2 Hz), 116.26 (d, ^2^*J*~C--F~ = 21.2 Hz), 114.69, 77.56, 76.92, 57.68, 46.74, 14.31; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~21~H~14~ClF~2~N~5~O~2~, 464.0696; found, 464.0699.

### 4.1.30. 3-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-7-(2-fluorobenzyl)-6-methyl-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8c**) {#sec4.1.30}

It was obtained in 74.3% yield; mp 143--146 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.85 (d, *J* = 9.3 Hz, 1H, Ar-H), 7.62 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.47--7.40 (m, 1H, Ar-H), 7.35--7.21 (m, 3H, Ar-H), 5.72 (s, 2H, NCH~2~), 4.94 (d, *J* = 2.2 Hz, 2H, C*H*~2~C≡CH), 3.68 (t, *J* = 2.2 Hz, 1H, CH~2~C≡C*H*), 2.62 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 159.97 (d, ^1^*J*~C--F~ = 247.0 Hz), 154.18, 152.58, 150.80 (d, ^1^*J*~C--F~ = 248.5 Hz), 149.39 (d, ^3^*J*~C--F~ = 2.8 Hz), 145.24, 130.59 (d, ^3^*J*~C--F~ = 8.1 Hz), 129.97 (d, ^3^*J*~C--F~ = 3.0 Hz), 125.47 (d, ^2^*J*~C--F~ = 11.0 Hz), 125.41 (d, ^3^*J*~C--F~ = 3.5 Hz), 124.94 (d, ^4^*J*~C--F~ = 3.3 Hz), 123.74 (d, ^3^*J*~C--F~ = 9.7 Hz), 122.15 (d, ^2^*J*~C--F~ = 14.3 Hz), 118.01 (d, ^2^*J*~C--F~ = 24.7 Hz), 115.72 (d, ^2^*J*~C--F~ = 20.8 Hz), 115.16, 79.29, 78.09, 57.24, 41.45 (d, ^4^*J*~C--F~ = 3.7 Hz), 13.74; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~21~H~14~ClF~2~N~5~O~2~, 442.0877; found, 442.0880.

### 4.1.31. 3-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-6-methyl-7-(pyridin-2-ylmethyl)-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8d**) {#sec4.1.31}

It was obtained in 70.2% yield; mp 171--174 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 8.58 (s, 1H, pyridine-H), 7.99 (t, *J* = 6.7 Hz, 1H, pyridine-H), 7.83 (d, *J* = 9.0 Hz, 1H, Ar-H), 7.62 (d, *J* = 6.8 Hz, 2H, pyridine-H, Ar-H), 7.47 (s, 1H, pyridine-H), 5.84 (s, 2H, NCH~2~), 4.95 (d, *J* = 1.1 Hz, 2H, C*H*~2~C≡CH), 3.66 (t, *J* = 1.4 Hz, 1H, CH~2~C≡C*H*), 2.62 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.81, 153.40, 152.62, 150.81 (d, ^1^*J*~C--F~ = 248.5 Hz), 149.40 (d, ^3^*J*~C--F~ = 2.0 Hz), 148.49, 145.33, 138.87, 125.47 (d, ^2^*J*~C--F~ = 14.4 Hz), 125.35, 123.76, 123.73 (d, ^3^*J*~C--F~ = 6.8 Hz), 122.67, 117.99 (d, ^2^*J*~C--F~ = 24.5 Hz), 115.18, 79.26, 78.08, 57.25, 47.27, 13.87; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~20~H~14~ClFN~6~O~2~, 425.0924; found, 425.0928.

### 4.1.32. 3-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-6-methyl-7-(1-phenylethyl)-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8e**) {#sec4.1.32}

It was obtained in 69.3% yield; mp 181--183 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.84 (d, *J* = 9.3 Hz, 1H, Ar-H), 7.62 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.44--7.32 (m, 5H, Ar-H), 6.12 (q, *J* = 7.0 Hz, 1H, NC*H*CH~3~), 4.94 (d, *J* = 1.8 Hz, 2H, C*H*~2~C≡CH), 3.68 (t, *J* = 1.8 Hz, 1H, CH~2~C≡C*H*), 2.63 (s, 3H, imidazole-CH~3~), 2.12 (d, *J* = 7.1 Hz, 3H, NCHC*H*~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.29, 153.08, 151.28 (d, ^1^*J*~C--F~ = 248.7 Hz), 149.89 (d, ^3^*J*~C--F~ = 2.5 Hz), 145.77, 139.91, 129.31, 128.51, 127.12, 126.22, 125.92 (d, ^2^*J*~C--F~ = 14.3 Hz), 124.20 (d, ^3^*J*~C--F~ = 9.7 Hz), 118.48 (d, ^2^*J*~C--F~ = 24.5 Hz), 115.62, 79.78, 78.61, 57.73, 55.73, 19.92, 15.22; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~22~H~17~ClFN~5~O~2~, 460.0947; found, 460.0950.

### 4.1.33. 3-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-6-methyl-7-phenyl-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8f**) {#sec4.1.33}

It was obtained in 73.2% yield; mp 188--191 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.86 (d, *J* = 9.2 Hz, 1H, Ar-H), 7.77--7.64 (m, 5H, Ar-H), 7.60 (d, *J* = 6.2 Hz, 1H, Ar-H), 4.97 (d, *J* = 1.4 Hz, 2H, C*H*~2~C≡CH), 3.67 (t, *J* = 1.4 Hz, 1H, CH~2~C≡C*H*), 2.52 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 153.88, 152.74, 150.81 (d, ^1^*J*~C--F~ = 248.5 Hz), 149.42 (d, ^3^*J*~C--F~ = 2.3 Hz), 145.82, 132.90, 130.11, 129.80, 127.60, 125.52, 125.41 (d, ^2^*J*~C--F~ = 14.1 Hz), 123.81 (d, ^3^*J*~C--F~ = 9.6 Hz), 118.07 (d, ^2^*J*~C--F~ = 24.6 Hz), 115.07, 79.33, 78.07, 57.24, 14.22; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~20~H~13~ClFN~5~O~2~, 432.0634; found, 432.0638.

### 4.1.34. 3-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-7-(3-fluorobenzyl)-6-methyl-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8g**) {#sec4.1.34}

It was obtained in 76.1% yield; mp 200--204 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.85 (d, *J* = 9.3 Hz, 1H, Ar-H), 7.62 (d, *J* = 6.4 Hz, 1H, Ar-H), 7.52--7.41 (m, 1H, Ar-H), 7.24--7.14 (m, 3H, Ar-H), 5.69 (s, 2H, NCH~2~), 4.95 (d, *J* = 1.8 Hz, 2H, C*H*~2~C≡CH), 3.68 (t, *J* = 1.8 Hz, 1H, CH~2~C≡C*H*), 2.59 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 162.81 (d, ^1^*J*~C--F~ = 245.4 Hz), 154.55, 153.15, 151.32 (d, ^1^*J*~C--F~ = 248.2 Hz), 149.90 (d, ^3^*J*~C--F~ = 2.5 Hz), 145.77, 138.59 (d, ^3^*J*~C--F~ = 7.6 Hz), 131.57 (d, ^3^*J*~C--F~ = 8.1 Hz), 126.03 (d, ^2^*J*~C--F~ = 14.1 Hz), 124.25 (d, ^3^*J*~C--F~ = 10.1 Hz), 118.53 (d, ^2^*J*~C--F~ = 24.7 Hz), 115.65, 115.51 (d, ^2^*J*~C--F~ = 21.5 Hz), 114.77 (d, ^2^*J*~C--F~ = 22.2 Hz), 79.82, 78.60, 57.75, 46.55, 14.32; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~21~H~14~ClF~2~N~5~O~2~, 464.0696; found, 464.0701.

### 4.1.35. 3-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-6-methyl-7-phenethyl-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8h**) {#sec4.1.35}

It was obtained in 71.3% yield; mp 195--197 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.83 (d, *J* = 9.2 Hz, 1H, Ar-H), 7.59 (d, *J* = 6.5 Hz, 1H, Ar-H), 7.30--7.22 (m, 3H, Ar-H), 7.13 (d, *J* = 6.6 Hz, 2H, Ar-H), 4.97 (d, *J* = 1.8 Hz, 2H, C*H*~2~C≡CH), 4.61 (t, *J* = 6.7 Hz, 2H, NC*H*~2~CH~2~), 3.68 (t, *J* = 1.8 Hz, 1H, CH~2~C≡C*H*), 3.17 (t, *J* = 6.6 Hz, 2H, NCH~2~C*H*~2~), 2.29 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.53, 153.11, 151.35 (d, ^1^*J*~C--F~ = 252.1 Hz), 149.90 (d, ^3^*J*~C--F~ = 2.6 Hz), 145.53, 137.90, 129.44, 128.98, 127.34, 126.14 (d, ^2^*J*~C--F~ = 14.1 Hz), 125.73, 124.30 (d, ^3^*J*~C--F~ = 9.8 Hz), 118.53 (d, ^2^*J*~C--F~ = 24.7 Hz), 115.64, 79.82, 78.61, 57.78, 45.78, 35.75, 13.73; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~22~H~17~ClFN~5~O~2~, 460.0947; found, 460.0951.

### 4.1.36. 3-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-7-(4-chlorophenyl)-6-methyl-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8i**) {#sec4.1.36}

It was obtained in 70.2% yield; mp 169--171 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.87 (d, *J* = 9.3 Hz, 1H, Ar-H), 7.78 (s, 4H, Ar-H), 7.58 (d, *J* = 6.6 Hz, 1H, Ar-H), 4.97 (d, *J* = 2.1 Hz, 2H, CH~2~C≡C*H*), 3.68 (t, *J* = 2.2 Hz, 1H, CH~2~C≡C*H*), 2.51 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, CDCl~3~): δ 153.43, 152.92, 151.48 (d, ^1^*J*~C--F~ = 252.5 Hz), 149.78 (d, ^3^*J*~C--F~ = 2.0 Hz), 145.54, 136.49, 131.21, 130.38, 128.41, 126.33, 125.74 (d, ^2^*J*~C--F~ = 9.1 Hz), 124.91 (d, ^2^*J*~C--F~ = 14.1 Hz), 118.55 (d, ^2^*J*~C--F~ = 14.1 Hz), 114.67, 77.50, 76.87, 57.67, 14.52; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~20~H~12~Cl~2~FN~5~O~2~, 466.0244; found, 466.0248.

### 4.1.37. 3-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-7-(2,4-difluorobenzyl)-6-methyl-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8j**) {#sec4.1.37}

It was obtained in 76.2% yield; mp 177--181 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.84 (d, *J* = 9.3 Hz, 1H, Ar-H), 7.63 (d, *J* = 6.5 Hz, 1H, Ar-H), 7.13 (td, ^3^*J*~H--F~ = 8.4 Hz, ^4^*J*~H--H~ = 1.8 Hz, 1H, Ar-H), 7.35 (td, ^3^*J*~H--F~ = 9.9 Hz, ^4^*J*~H--H~ = 2.1 Hz, 1H, Ar-H), 7.51--7.44 (m, 1H, Ar-H), 7.13 (m, 1H, Ar-H), 5.69 (s, 2H, NCH~2~), 4.95 (d, *J* = 1.8 Hz, 2H, C*H*~2~C≡CH), 3.67 (t, *J* = 1.8 Hz, 1H, CH~2~C≡C*H*), 2.62 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): 162.75 (dd, ^1^*J*~C--F~ = 248.5 Hz, ^3^*J*~C--F~ = 12.4 Hz), 160.72 (dd, ^1^*J*~C--F~ = 249.8 Hz, ^3^*J*~C--F~ = 12.5 Hz), 154.62, 153.07, 151.29 (d, ^1^*J*~C--F~ = 248.6 Hz), 149.89 (d, ^3^*J*~C--F~ = 2.0 Hz), 145.70, 132.23, 132.14 (dd, ^3^*J*~C--F~ = 5.1 Hz, ^3^*J*~C--F~ = 4.9 Hz), 125.95 (d, ^2^*J*~C--F~ = 14.6 Hz), 124.25 (d, ^3^*J*~C--F~ = 9.8 Hz), 119.12 (dd, ^2^*J*~C--F~ = 14.2 Hz, ^4^*J*~C--F~ = 3.6 Hz), 119.12 (dd, ^2^*J*~C--F~ = 14.2 Hz, ^4^*J*~C--F~ = 3.6 Hz), 118.50 (d, ^2^*J*~C--F~ = 24.7 Hz), 115.63, 112.48 (dd, ^2^*J*~C--F~ = 21.4 Hz, ^4^*J*~C--F~ = 3.4 Hz), 104.85 (t, ^2^*J*~C--F~ = 26.0 Hz), 79.78, 78.58, 57.74, 41.58, 14.27; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~21~H~13~ClF~3~N~5~O~2~, 460.0783; found, 460.0787.

### 4.1.38. 7-Benzyl-3-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-6-methyl-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8k**) {#sec4.1.38}

It was obtained in 75.8% yield; mp 192--195 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.85 (d, *J* = 9.3 Hz, 1H, Ar-H), 7.64 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.49--7.37 (m, 3H, Ar-H), 7.33 (d, *J* = 6.8 Hz, 2H, Ar-H), 5.67 (s, 2H, NCH~2~), 4.95 (d, *J* = 2.1 Hz, 2H, C*H*~2~C≡CH), 3.68 (t, *J* = 2.1 Hz, 1H, CH~2~C≡C*H*), 2.60 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, CDCl~3~): δ 153.54, 153.04, 151.67 (d, ^1^*J*~C--F~ = 252.2 Hz), 149.79 (d, ^3^*J*~C--F~ = 2.9 Hz), 145.35, 134.13, 129.32, 128.79, 127.37, 126.12, 125.78 (d, ^3^*J*~C--F~ = 9.4 Hz), 125.17 (d, ^2^*J*~C--F~ = 14.2 Hz), 118.62 (d, ^2^*J*~C--F~ = 24.4 Hz), 114.85, 77.20, 77.15, 76.78, 57.73, 47.45, 14.41; HRMS (ESI) *m*/*z*: \[M + H\]^+^ calcd for C~21~H~15~ClFN~5~O~2~, 424.0971; found, 424.0975.

### 4.1.39. 3-(4-Chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-7-(4-chlorobenzyl)-6-methyl-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8l**) {#sec4.1.39}

It was obtained in 75.6% yield; mp 199--200 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.85 (d, *J* = 9.3 Hz, 1H, Ar-H), 7.62 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.47 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.37 (d, *J* = 8.4 Hz, 2H, Ar-H), 5.67 (s, 2H, NCH~2~), 4.95 (d, *J* = 2.1 Hz, 2H, C*H*~2~C≡CH), 3.68 (t, *J* = 2.1 Hz, 1H, CH~2~C≡C*H*), 2.60 (s, 3H, imidazole-CH~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.00, 152.60, 150.82 (d, ^1^*J*~C--F~ = 248.7 Hz), 149.40 (d, ^3^*J*~C--F~ = 2.5 Hz), 145.21, 134.33, 132.78, 129.30, 128.92, 125.50 (d, ^2^*J*~C--F~ = 14.4 Hz), 125.47, 123.77 (d, ^3^*J*~C--F~ = 9.8 Hz), 118.02 (d, ^2^*J*~C--F~ = 24.6 Hz), 115.16, 79.29, 78.09, 57.26, 45.96, 13.83; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~21~H~14~Cl~2~FN~5~O~2~, 480.0401; found, 480.0405.

### 4.1.40. 7-Benzyl-3-(4-chloro-2-fluoro-5-(prop-2-yn-1-yloxy)phenyl)-6-ethyl-3*H*-imidazo\[4,5-*d*\]\[1,2,3\]triazin-4(7*H*)-one (**8m**) {#sec4.1.40}

It was obtained in 72.4% yield; mp 200--201 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 7.85 (d, *J* = 9.3 Hz, 1H, Ar-H), 7.63 (d, *J* = 6.6 Hz, 1H, Ar-H), 7.44--7.29 (m, 3H, Ar-H), 7.31 (d, *J* = 7.1 Hz, 2H, Ar-H), 5.68 (s, 2H, NCH~2~), 4.95 (d, *J* = 2.2 Hz, 2H, C*H*~2~C≡CH), 3.68 (t, *J* = 2.2 Hz, 1H, CH~2~C≡C*H*), 2.92 (q, *J* = 7.4 Hz, 2H, imidazole-C*H*~2~CH~3~), 1.26 (t, *J* = 7.4 Hz, 3H, imidazole-CH~2~C*H*~3~); ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 158.02, 152.74, 150.83 (d, ^1^*J*~C--F~ = 248.7 Hz), 149.40 (d, ^3^*J*~C--F~ = 2.2 Hz), 145.29, 135.48, 128.95, 128.07, 127.14, 125.54 (d, ^2^*J*~C--F~ = 14.3 Hz), 125.38, 123.73 (d, ^3^*J*~C--F~ = 9.8 Hz), 118.02 (d, ^2^*J*~C--F~ = 24.6 Hz), 115.17, 79.30, 78.09, 57.24, 46.30, 20.32, 10.80; HRMS (ESI) *m*/*z*: \[M + Na\]^+^ calcd for C~22~H~17~ClFN~5~O~2~, 460.0947; found, 460.0950.

4.2. Herbicidal Activity Assay {#sec4.2}
------------------------------

### 4.2.1. General {#sec4.2.1}

Two broadleaf plants and two grasses including amaranth pigweed (*A. retroflexus*), rape (*B. campestris*), crab grass (*D. sanguinalis*), and barnyard grass (*E. crusgalli*) were used to test the herbicidal activity of title compounds. Seeds of amaranth pigweed, barnyard grass, and crab grass were reproduced outdoors and stored at 4 °C. Seeds of rape were bought from Institute of Crop, Tianjin Agriculture Science Academy.

### 4.2.2. Culture {#sec4.2.2}

Seeds were planted in 7.0 cm-diameter disposable paper cup (250 mL) containing artificial mixed soil. Before plant emergence, the cups were covered with plastic film to keep them moist. Plants were grown in the green house. After 21 days, fresh weight of upground plants was measured after treatment.

### 4.2.3. Treatment {#sec4.2.3}

Dosage (activity ingredient) for each compound is 1500 g per ha. Purified compounds were dissolved in 100 μL *N*,*N*-dimethylformamide with the addition of a little Tween 20, and then were sprayed using a laboratory belt sprayer delivering at 750 L/ha-spray-volume. The same amount of water was sprayed as control. Preemergency treatment: compounds were sprayed immediately after seeds planting. Two replicates each treatment. Postemergency: compounds were sprayed after the first true leave expanding. The inhibition percent of upground fresh weight is used to describe the control efficiency of compounds.

4.3. Antitumor Activity Assay {#sec4.3}
-----------------------------

The cell lines used for the antitumor test were liver hepatocellular carcinoma HepG-2 and U-118 MG strocytic glioblastoma. Cells were maintained in the growth medium Dulbecco's modified Eagle's medium low glucose under a humidified atmosphere of 5% CO~2~ at 37 °C. The cell line was refreshed according to the routine method to reach 70--80% cell confluence. Freshly trypsinized cell suspensions were seeded in 96-well microtiter plates at densities of 3000 cells per well with compounds. After 72 h in culture with test compounds, 10 μL 5 mg/mL MTT was added per well and OD values of every well were recorded using microplate reader at 570 nm. Vehicle (dimethyl sulfoxide) was used as a control. The data were processed by excel software to calculate the inhibition rate at different concentrations, and the IC~50~ values were fitted by SPSS. Inhibiton rate (%) = {1 -- (experimental OD value -- blank OD value)/(control OD value -- blank OD value)} × 100%.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.9b02495](http://pubs.acs.org/doi/abs/10.1021/acsomega.9b02495).Chemical structures of the compounds of title compounds; ^1^H NMR, ^13^C NMR, and HRMS spectra ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02495/suppl_file/ao9b02495_si_001.pdf))
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